Moreover, complementary studies (e.g., Western Blot, immunocytochemistry and trans-well invasion assays) showed that SK228 severely reduced A549 and CL15 tumor cell line’s invasion characteristics through FAK/Paxillin pathway disruption, thus providing support for SK228 clinical translation as an inhibitor of highly metastatic tumor cells [30]. The gene discussed is PTK2; the disease is neoplasm.